TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...
Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...
10 September 2025
Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group
The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer...
3 September 2025
Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...
10 September 2025
Filter & search
Fund strategy:
Loading...
These were all articles
f88a62ef2c